Truvada, Emtriva, Viread and Hepsera are registered trademarks of Gilead Sciences, Atripla is a registered trademark of Bristol-Myers Squibb & Gilead Sciences,Source: Gilead Sciences, IncGilead Sciences announced today that a Phase II clinical trial of its investigational integrase inhibitor-based, once-daily fixed-dose ‘Quad ‘regimen of elvitegravir, GS 9350 and Truvada for the treatment of HIV – 1 infection met its primary objective malegra reviews more info . The ongoing study of 71 HIV-infected, with ritonavir adults compares the Quad with Atripla . Based on 24 – week data, efficacy of the Quad met the statistical criteria of non-inferiority as compared to Atripla based on the proportion of patients with HIV RNA levels of less than 50 copies / mL. Discontinuation rates due to adverse events were comparable in both arms of the study. Full study results will at a scientific conference at a scientific conference in spring 2010.
About the GS 9350 Phase II studyThe GS 9350 Phase II trial is a double blind, multicenter, randomized , active-controlled, 48-week clinical trial evaluating the safety and efficacy of GS 9350 reinforced atazanavir compared to ritonavir-boosted atazanavir , each in combination with Truvada in HIV-infected treatment-naive adults with HIV RNA levels greater than or equal to 5,000 copies / mL and CD4+ cell counts greater than 50 cells/mm3. Entry criteria required that patients are nucleoside reverse nucleoside reverse transcriptase inhibitors, non – nucleoside reverse transcriptase inhibitor or primary protease inhibitor resistance mutations, such as the International AIDS Society – USA guidelines, and no prior use of antiretroviral treatment.
Impact on the lasers technology in 2010 AAAS Annual Meeting Emphasized As a part of Laser Solid, to one year the Anniversary of the first working laser, the Optical Society and the American Physical Society annual meeting. Seminar on seminar titled The History and Future of Laser Technology place in the sitting, as of world’s largest an interdisciplinary science forum. – Speakers to first symposium entitled, We celebrate the birthday of the lasers: Looking back in 50 years discusses the story how of laser came to be and recounted the early growth of this omnipresent instrument. Soon as a human embryo research search engine no clear application beyond the laboratory also presented lecturers that of the lasers as transformative technology of the 20th Th century recognized to huge scientific, commercial, industrial, and societal relevance. In addition, places his influence on M to expedite in the health and communication to national security and entertainment. Presenters included Anthony Siegman from Stanford University discuss What to have reached to the lasers, William B. Jumpers of Californian Institute of Technology, will speak on Gas laser: The Early Years , and Jeff Hecht of Laser Focus World tray who introduced Looking Back at How designed that lasers. There can be no better example of the effects pure scientific research to the company as the history of the laser, said Anthony J. Campillo, senior director Scientific Policy OSA and co-organizer the first symposium. Vie just through the transistor, it example how example of how Labor science leads to untold applications and benefits to society. Addressing laser in the Extreme, symposium organizer Thomas M. CEO of the Stanford Photonics Research centers, of of the newest applications of lasers having moderated by:.
Turning physicians a photoacoustic tomography, a combination of laser and ultrasound to be used, in order to cavernous tissue penetrating and light cell activity from disease recorded, and.